期刊文献+

帕金森病运动并发症治疗进展 被引量:7

Progress on treatment of Parkinson's disease and its motor complications
下载PDF
导出
摘要 帕金森病(Parkinson’s disease,PD)是一种进行性神经元变性疾病。随着病程进展,左旋多巴的疗效逐渐减退,最终出现多种类型运动并发症,主要包括剂末现象、异动症、步态冻结、肌张力障碍;特别是疾病进展期的患者出现异动症及肌张力障碍等并发症时,临床治疗难度大。病程6~9年的PD患者中,41%~70%的患者存在运动并发症。本文通过广泛查阅国内外文献,综述目前处理PD运动并发症的策略,为临床医师认识以及处理PD运动并发症提供参考。 Parkinson's disease(PD)is a progressive neuron degeneration disease,the patient^response to pharmacotherapy decreases as time goes by,resulting in various motor complications,mainly includes wearing-off-,freezing of gait(FOG),dyskinesia,dys-tonia.The occurrence of motor complications is a key component of PD and presents a clinical challenge to practitioners.Especially the occurrence of dyskinesia and dystonia in patients with advanced disease further complicates clinical management.The prevalence of movement problems,is reported to be as high as41%to70%in PD patients after six to nine years of treatment.This article makes a re-view about the way to deal with motor complications through reading literature in detail,so as to provide reference for clinicians under-standing and dealing with motor complications.
作者 李成刚 李成国 LI Cheng-gang;LI Cheng-guo(Neurology Department, Fengdu People's Hospital, Fengdu 408200;Neurology Department, Chongqing Red Cross Hostipal ,Jiangbei District People's Hostipal, Jiangbei 400020 , Chongqing, China)
出处 《川北医学院学报》 CAS 2017年第4期643-648,共6页 Journal of North Sichuan Medical College
关键词 帕金森病 运动并发症 异动症 肌张力障碍 治疗 Parkinson’ s disease (PD) Motor complication Dyskinesia Dystonia Therapy
  • 相关文献

参考文献1

二级参考文献32

  • 1Ahlskog JE, Muenter MD. Frequency of L-dopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Dis- ord,2001,16 :448-458.
  • 2Van Gerpen JA, Kumar N, Bower ]H, et al. Levedopa-associated dyski- nesia risk among Parkinson disease patients in Olmsted County, Minne- sota, 1976 -1990.
  • 3Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord ,2001,16:448-458.
  • 4Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treat- ment of Parkinson' s disease : scientific rationale and clinical implica- tions. Lancet Neurol,2006 ,5 :677-687.
  • 5Katzenschlager R, Lees AJ. Treatment of Parkinson ' s disease : L-dopa as the first choice. J Neuro1,2002,249( Suppl 2 ) :S19-24.
  • 6Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkin- son' s disease. Clin Pharmacokinet,2002,41:261-309.
  • 7Pierantozzi M, Pietroiusti A, Brusa L, et al. Helicobacter pylori eradica- tion and L-dopa absorption in patients with PD and motor fluctuations. Neurology ,2006,66 : 1824-1829.
  • 8Devos D. Patient profile, indications, efficacy and safety of duodenal L- dopa infusion in advaneed Parkinson' s disease. Mov Disord ,2009,24: 993-1000.
  • 9Nyholm D, Lewander T, Johansson A, et al. Enteral L-dopa/carbidopa infusion in advanced Parkinsan disease:long-term exposure. Clin Nan- ropharmacol, 2008,31 : 63 -73.
  • 10OndoWG, Shinawi L, Moore S. Comparison of orally dissolving earbido- pa/L-dopa(Parcopa) to conventional oral carbidopa/L-dopa: a single- dose, double-blind, double-dummy, placebo-controlled, crossover trial. Mov Disord ,2010,25:2724-2727.

共引文献2

同被引文献125

引证文献7

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部